Day: January 8, 2024

Vornado’s PENN 2Seventh Avenue between 31st and 33rd StreetsNEW YORK, Jan. 08, 2024 (GLOBE NEWSWIRE) — Vornado Realty Trust (NYSE:VNO) today named Cushman & Wakefield as the exclusive leasing agent of PENN 2, its 1.8 million square-foot PENN DISTRICT office tower. Vornado’s PENN 2Seventh Avenue between 31st and 33rd Streets The Cushman & Wakefield agency team will be led by Bruce Mosler and Josh Kuriloff, who have recently been responsible for more than 7.7 million square feet in office leasing across Midtown Manhattan’s burgeoning West Side. PENN 2 has been completely transformed into a world-class office environment geared toward today’s leading companies. The $750 million full-building redevelopment includes a highly efficient modern glass curtain wall; a striking triple-height lobby; 16 distinctive...

OP-3136 demonstrated potent anti-tumor activity alone and in combination with both palazestrant and CDK4/6 inhibitors in preclinical ER+ breast cancer models Initiating IND-enabling studies with goal to advance into clinical development by end of 2024 SAN FRANCISCO, Jan. 08, 2024 (GLOBE NEWSWIRE) — Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, today announced the selection of a development candidate for the Company’s program targeting KAT6, an epigenetic target that is dysregulated in breast cancer and other cancers. The compound, named OP-3136, is an orally bioavailable, potent KAT6A/B-selective inhibitor developed by Olema in collaboration with Aurigene Oncology. “We...

— Polymorph and Stereoisomer Patents when Issued Extend Portfolio to at least 2045 — — Polymorph and Stereoisomer Patent Filings Continue to Expand Patent Portfolio — SOUTH SAN FRANCISCO, Calif. and MIAMI, Jan. 08, 2024 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical stage biotechnology company focused on the discovery, research, and development of innovative treatments for Central Nervous System (CNS) disorders, today announced the invention of a crystalline form of PAS-004 which is captured in polymorph and stereoisomer patent filings that when issued we believe will extend patent protection to at least 2045. Chief Development Officer Dr. Graeme Currie stated, “Through the invention of the crystal structure for PAS-004 and subsequent patent filings,...

TORONTO, Jan. 08, 2024 (GLOBE NEWSWIRE) —  Mattr Corp. (formerly Shawcor Ltd.) (“Mattr” or the “Company”) (TSX: MATR) announced today that it has filed articles of amendment in accordance with the Canada Business Corporations Act and, effective today, completed its legal name change to Mattr Corp. pursuant to such filing (the “Name Change”). The Company first announced its intention to change its name on September 12, 2022, with the Company’s common shareholders approving the Name Change on May 12, 2023, at the Company’s annual and special meeting of shareholders. On June 7, 2023, the Company announced its rebranding to “Mattr” and began conducting business as “Shawcor Ltd. dba Mattr Infratech”. “The Company rebranded last summer, utilizing a dba structure to facilitate a simplified sale process for its pipeline coating business,”...

STAMFORD, Conn., Jan. 08, 2024 (GLOBE NEWSWIRE) — SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, will present today at the 42nd Annual J.P. Morgan Healthcare Conference at 7:30 a.m. PT (10:30 a.m. ET), and a live webcast will be available at ir.springworkstx.com. Ahead of the presentation, the Company highlighted its 2023 accomplishments and announced its anticipated key milestones for 2024. 2023 Accomplishments NirogacestatReceived approval from the United States Food and Drug Administration (FDA) for OGSIVEO™ (nirogacestat), an oral gamma secretase inhibitor, for the treatment of adult patients with progressing desmoid tumors who require systemic treatment. Published data from the Phase 3 DeFi trial of nirogacestat in adult patients...

Company hires technology veteran to accelerate its transformation and drive profitable growth IRVINE, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) — CalAmp (Nasdaq: CAMP), a connected intelligence company helping people and organizations improve operational performance with telematics solutions, is pleased to announce that Chris Adams will be joining the company as President and Chief Executive Officer (CEO), effective January 22, 2024. Adams is an accomplished technology leader who brings a wealth of knowledge and experience to CalAmp. He possesses a unique combination of technical depth, operational skills, and general management experience from a broad range of technology companies – most recently as VP/GM of the Automotive Sensing Division at onsemi. “After a comprehensive search process, we are pleased to welcome Chris as CalAmp’s...

Miami, Jan. 07, 2024 (GLOBE NEWSWIRE) — Hut 8 Corp. (Nasdaq | TSX: HUT), (“Hut 8” or the “Company”) one of North America’s largest, most innovative digital asset mining pioneers and high performance computing infrastructure providers announces that it has received an approval and vesting order (the “Approval and Vesting Order“) from the Ontario Superior Court of Justice (Commercial List) in the context of the ongoing proceedings pursuant to the Companies’ Creditors Arrangement Act of Validus Power Corp. (“VPC“) and certain of its subsidiaries (collectively, the “Validus Entities“). Among other things, the Approval and Vesting Order approves the Company’s previously announced stalking horse bid transaction (the “Transaction“) to acquire four natural gas power plants...

MIAMI, Jan. 08, 2024 (GLOBE NEWSWIRE) — Hut 8 Corp. (Nasdaq | TSX: HUT), (“Hut 8” or the “Company”) one of North America’s largest, most innovative digital asset mining pioneers and high performance computing infrastructure providers announces that it has received an approval and vesting order (the “Approval and Vesting Order“) from the Ontario Superior Court of Justice (Commercial List) in the context of the ongoing proceedings pursuant to the Companies’ Creditors Arrangement Act of Validus Power Corp. (“VPC“) and certain of its subsidiaries (collectively, the “Validus Entities“). Among other things, the Approval and Vesting Order approves the Company’s previously announced stalking horse bid transaction (the “Transaction“) to acquire four natural gas power plants...

First Patient Dosed and Successfully Engrafted in BEACON Phase 1/2 Trial of BEAM-101 in Patients with Severe Sickle Cell Disease; Significant Enrollment Progress Supports First Expected Clinical Data Readout in Second Half of 2024 European Clinical Trial Application (CTA) Submitted for BEAM-302; Trial Initiation in Alpha-1 Antitrypsin Deficiency Planned for First Half of 2024 Investigational New Drug (IND) Application for BEAM-301 On-track for First Half of 2024 Cash Runway Expected to Support Operating Plans into 2027 CAMBRIDGE, Mass., Jan. 08, 2024 (GLOBE NEWSWIRE) — Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported progress across the company’s hematology and genetic disease portfolios and provided updates on anticipated upcoming milestones. “Our...